AI in practice: 4 real-world use cases in health and life sciences
March 5, 2026 |
Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it is applied to clearly defined challenges, embedded into existing workflows, and paired with deep domain expertise.
Across health and life sciences, organizations are moving beyond experimentation and focusing on how AI can support better decisions, more efficient operations, and clearer communication. At Inizio, these capabilities are central to how we drive Intelligent Commercialization™ – connecting data, insight, and expertise to help teams act with greater clarity and confidence. The following four use cases from across Inizio illustrate what that looks like in real-world settings – supporting operational performance, insight generation, engagement strategies, and strategic decision-making across the commercialization journey.
How did Inizio Engage scale call monitoring with AI-powered speech analytics?
Traditional call monitoring approaches often limit both scale and consistency, with only a small proportion of interactions reviewed and feedback delivered retrospectively. In this use case, Inizio Engage applied AI-powered speech analytics to analyze calls at scale, enabling patterns, risks, and performance indicators to be identified more efficiently and consistently across large volumes of interactions.
By automating the analysis of call content, our client was able to move beyond manual sampling and focus attention where it mattered most. The approach supported more targeted coaching and quality assurance, helping improve agent performance while maintaining oversight across a significantly broader set of calls.
How did Inizio Evoke turn digital insights into smarter HCP engagement with hematologic oncologists?
Engaging hematologic oncologists effectively requires a clear understanding of how they seek, consume, and respond to information. In this example, Inizio Evoke used Narratev™, a product in their Cognitev™ platform, to uncover real-world engagement behaviors, moving beyond surface-level metrics to identify patterns that could inform more relevant and timely interactions.
By translating these insights into practical recommendations, our client was able to align engagement strategies more closely with oncologists’ information needs and preferences. This helped support more focused decision-making and enabled engagement approaches that were better grounded in observable behavior rather than assumptions.
How did Inizio Ignite accelerate indication strategy in rare endocrine disorders?
Developing an effective indication strategy in rare endocrine disorders requires teams to assess a wide range of potential opportunities while balancing scientific feasibility, commercial considerations, and internal alignment. In this example, Inizio Ignite used AssetNav, part of their Navigator AI™ platform, to evaluate and prioritize potential indications, enabling more informed and objective strategic discussions.
By applying consistent criteria and integrating insights across functions, teams were able to narrow a broad set of possibilities into a focused, prioritized shortlist. This supported clearer decision-making, faster alignment, and a more repeatable approach to indication planning that could be applied beyond a single strategic exercise.
How did Inizio Medical elevate MSL performance with AI-enabled field intelligence?
Medical Science Liaisons (MSLs) generate vast amounts of valuable insight through their interactions with healthcare professionals, yet much of this intelligence can be difficult to capture, structure, and apply consistently. Inizio Medical built iON AI™ HCP Interact to help transform unstructured field insights into actionable intelligence that could be shared across medical and commercial teams.
By using AI to synthesize insights from MSL activity, organizations can surface emerging themes, identify unmet needs, and support more consistent scientific exchange. This enables MSLs to spend less time on manual reporting and more time on high-value engagement, with clearer visibility into field insights to inform strategy and planning.
Taking AI from potential to practice
The impact of AI is not defined by the technology alone, but by how it is applied to real challenges and real decisions. When paired with human expertise and grounded in strong data foundations, AI becomes a powerful enabler of more focused action and measurable progress.
Rather than replacing existing processes, each example shows AI working alongside teams – extending their ability to monitor, understand, and act at scale. This is how Inizio helps organizations drive Intelligent Commercialization™ – using platforms, products, and solutions to turn insight into action and complexity into clarity across the pharma lifecycle.
Discover how Intelligent Commercialization™ is built to deliver real-world results.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Healthcare in the age of AI: How will artificial intelligence impact future decision-making?
Authored by: Constanza Salas, Jhon Galindo and Rachel Howard
Therapy Watch launches new tracker covering Postpartum Depression
The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry
Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market
Authored by: Marc Garcia and Tania Rodrigues
Infographic: Rare Diseases in China
How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
New syndicated COPD report now available
Living with COPD 2023
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.
Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer
With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.
Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI
Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.
Article: Creating truly effective communications – the impact of high speed, high octane messaging
In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.
Research Partnership makes two senior appointments to bolster its US and MedTech operations
Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.